3D Printed Drugs Market by Drug (Spritam and Others); by Region (U.S., Rest of North America, France, UK, Germany, Spain, Italy, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, GCC Countries, Southern Africa, Rest of MEA, Brazil, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2018-2030

Report ID :AMI-143 | Category : Therapeutic Area | Published Date :November, 2018 | Pages : 312 | Format :PDF
Buy Now!

Industry Trends:

3D printing has starting to gain popularity in the healthcare market after being approved by the Food and Drug Administration in 2015. Some selective manufacturing techniques such as stereolithography, laser sintering, inkjet printing, binder deposition, extrusion-based printing, and fused deposition would gradually gain adoption with commercialization of these drugs in the coming years. This science binds the layers of medicinal powder together using an interactive layer of liquid, which solders the ingredients. Sequential casting process can produce unique release profiles such as flexibility and streamlined production. Also, hydrogels or polymer-based filaments are used for printing drugs products. The ability of 3D printing solutions to facilitate on-the-spot drug fabrication at times of emergencies is a major advantage of drugs printed using 3D printing technique.

3D printing of drugs has enabled facile fabrication of multi-layer delivery systems with geometric and architectural complexity. In coming years, the technology is expected to facilitate next-level of individualization and personalization in drug dosing that is almost impossible using conventional mass-scale production methods. However, there are potential risks associated with precision and release characteristics of these drugs and the market is therefore, still at a very early stage. Point-of-care is a unique feature presented by 3D printing and it can be associated with the future of pharmaceutical industry as it effectively fulfills the niche portion of drug manufacturing.

Global 3D Printed Drugs Market is expected to grow with a CAGR of 6.2% during the forecast period of 2018 to 2030. The study analyzes the market in terms of revenue and sales volume across all the major markets.

The U.S. 3D Printed Drugs Revenue, 2017-2026

3D Printed Drugs Market

3D Printed Drugs Market, by Drug:

Spritam drug was produced for the treatment of seizures, for people suffering from epilepsy and was initially made available in the U.S. market during early 2016. This drug is easy to consume due to its solubility properties and is therefore, helpful for these patients to easily administer the drug. The rising incidences of epilepsy and growing demand for easily soluble drugs is propelling the demand for Spritam drugs market.

Competitive Landscape:

The 3D Printed Drugs Market report provides both, qualitative and quantitative research of the market, as well as provides worthy insights into the rational scenario and favored development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and detailed insights on the competitiveness of these players. The key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by the major players are also recognized and analyzed in the report. For each company, the report recognizes their headquarter, competitors, product/service type, application and specification, pricing, and gross margin.

Some of the primary participants in the 3D Printed Drugs market includes Aprecia Pharmaceuticals, 3D Printer Drug Machine, Hewlett Packard Caribe, BV, LLC, GlaxoSmithKline Plc., and FabRx Ltd. amongst others.

1.    Introduction

1.1.   Market Scope

1.2.   Market Segmentation

1.3.   Methodology

1.4.   Assumptions

2.    3D Printed Drugs Market Snapshot

3.    Executive Summary: 3D Printed Drugs Market

4.    Qualitative Analysis: 3D Printed Drugs Market

4.1.   Introduction

4.1.1.   Product Definition

4.1.2.   Industry Development

4.2.   Market Dynamics

4.2.1.   Drivers

4.2.2.   Restraints

4.2.3.   Opportunities

4.3.   Trends in 3D Printed Drugs Market

5.    Global 3D Printed Drugs Market Analysis and Forecasts, 2018 – 2026

5.1.   Overview

5.1.1.   Global 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts

5.2.   Global 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

5.2.1.   Spritam

5.2.1.1. Definition

5.2.1.2. Market Penetration

5.2.1.3. Market Revenue Expected to Increase by 2026

5.2.1.4. Compound Annual Growth Rate (CAGR)

5.2.2.   Others

5.2.2.1. Definition

5.2.2.2. Market Penetration

5.2.2.3. Market Revenue Expected to Increase by 2026

5.2.2.4. Compound Annual Growth Rate (CAGR)

5.3.   Key Segment for Channeling Investments

5.3.1.   By Drug

6.    North America 3D Printed Drugs Market Analysis and Forecasts, 2018 – 2026

6.1.   Overview

6.1.1.   North America 3D Printed Drugs Market Revenue (US$ Mn)

6.2.   North America 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

6.2.1.   Spritam

6.2.2.   Others

6.3.   North America 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Country

6.3.1.   U.S.

6.3.1.1. U.S. 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

6.3.1.1.1. Spritam

6.3.1.1.2. Others

6.3.2.   Rest of North America

6.3.2.1. Rest of North America 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

6.3.2.1.1. Spritam

6.3.2.1.2. Others

6.4.   Key Segment for Channeling Investments

6.4.1.   By Country

6.4.2.   By Drug

7.    Europe 3D Printed Drugs Market Analysis and Forecasts, 2018 – 2026

7.1.   Overview

7.1.1.   Europe 3D Printed Drugs Market Revenue (US$ Mn)

7.2.   Europe 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

7.2.1.   Spritam

7.2.2.   Others

7.3.   Europe 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Country

7.3.1.   France

7.3.1.1. France 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

7.3.1.1.1. Spritam

7.3.1.1.2. Others

7.3.2.   The UK

7.3.2.1. The UK 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

7.3.2.1.1. Spritam

7.3.2.1.2. Others

7.3.3.   Spain

7.3.3.1. Spain 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

7.3.3.1.1. Spritam

7.3.3.1.2. Others

7.3.4.   Germany

7.3.4.1. Germany 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

7.3.4.1.1. Spritam

7.3.4.1.2. Others

7.3.5.   Italy

7.3.5.1. Italy 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

7.3.5.1.1. Spritam

7.3.5.1.2. Others

7.3.6.   Rest of Europe

7.3.6.1. Rest of Europe 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

7.3.6.1.1. Spritam

7.3.6.1.2. Others

7.4.   Key Segment for Channeling Investments

7.4.1.   By Country

7.4.2.   By Drug

8.    Asia Pacific 3D Printed Drugs Market Analysis and Forecasts, 2018 – 2026

8.1.   Overview

8.1.1.   Asia Pacific 3D Printed Drugs Market Revenue (US$ Mn)

8.2.   Asia Pacific 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

8.2.1.   Spritam

8.2.2.   Others

8.3.   Asia Pacific 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Country

8.3.1.   China

8.3.1.1. China 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

8.3.1.1.1. Spritam

8.3.1.1.2. Others

8.3.2.   Japan

8.3.2.1. Japan 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

8.3.2.1.1. Spritam

8.3.2.1.2. Others

8.3.3.   India

8.3.3.1. India 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

8.3.3.1.1. Spritam

8.3.3.1.2. Others

8.3.4.   Southeast Asia

8.3.4.1. Southeast Asia 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

8.3.4.1.1. Spritam

8.3.4.1.2. Others

8.3.5.   Rest of Asia Pacific

8.3.5.1. Rest of Asia Pacific 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

8.3.5.1.1. Spritam

8.3.5.1.2. Others

8.4.   Key Segment for Channeling Investments

8.4.1.   By Country

8.4.2.   By Drug

9.    Middle East & Africa 3D Printed Drugs Market Analysis and Forecasts, 2018 – 2026

9.1.   Overview

9.1.1.   Middle East & Africa 3D Printed Drugs Market Revenue (US$ Mn)

9.2.   Middle East & Africa 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

9.2.1.   Spritam

9.2.2.   Others

9.3.   Middle East & Africa 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Country

9.3.1.   GCC Countries

9.3.1.1. GCC Countries 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

9.3.1.1.1. Spritam

9.3.1.1.2. Others

9.3.2.   Southern Africa

9.3.2.1. Southern Africa 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

9.3.2.1.1. Spritam

9.3.2.1.2. Others

9.3.3.   Rest of MEA

9.3.3.1. Rest of MEA 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

9.3.3.1.1. Spritam

9.3.3.1.2. Others

9.4.   Key Segment for Channeling Investments

9.4.1.   By Country

9.4.2.   By Drug

10. Latin America 3D Printed Drugs Market Analysis and Forecasts, 2018 – 2026

10.1. Overview

10.1.1. Latin America 3D Printed Drugs Market Revenue (US$ Mn)

10.2. Latin America 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

10.2.1. Spritam

10.2.2. Others

10.3. Latin America 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Country

10.3.1. Brazil

10.3.1.1. Brazil 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

10.3.1.1.1. Spritam

10.3.1.1.2. Others

10.3.2. Rest of Latin America

10.3.2.1. Rest of Latin America 3D Printed Drugs Market Revenue (US$ Mn) and Forecasts, By Drug

10.3.2.1.1. Spritam

10.3.2.1.2. Others

10.4. Key Segment for Channeling Investments

10.4.1. By Country

10.4.2. By Drug

11. Competitive Benchmarking

11.1. Player Positioning Analysis

11.2. Global Presence and Growth Strategies

12. Player Profiles

12.1. GlaxoSmithKline Plc.

12.1.1. Company Details

12.1.2. Company Overview

12.1.3. Product Offerings

12.1.4. Key Developments

12.1.5. Financial Analysis

12.1.6. SWOT Analysis

12.1.7. Business Strategies

12.2. 3D Printer Drug Machine

12.2.1. Company Details

12.2.2. Company Overview

12.2.3. Product Offerings

12.2.4. Key Developments

12.2.5. Financial Analysis

12.2.6. SWOT Analysis

12.2.7. Business Strategies

12.3. Aprecia Pharmaceuticals

12.3.1. Company Details

12.3.2. Company Overview

12.3.3. Product Offerings

12.3.4. Key Developments

12.3.5. Financial Analysis

12.3.6. SWOT Analysis

12.3.7. Business Strategies

12.4. Hewlett Packard Caribe

12.4.1. Company Details

12.4.2. Company Overview

12.4.3. Product Offerings

12.4.4. Key Developments

12.4.5. Financial Analysis

12.4.6. SWOT Analysis

12.4.7. Business Strategies

12.5. BV, LLC

12.5.1. Company Details

12.5.2. Company Overview

12.5.3. Product Offerings

12.5.4. Key Developments

12.5.5. Financial Analysis

12.5.6. SWOT Analysis

12.5.7. Business Strategies

12.6. FabRx Ltd

12.6.1. Company Details

12.6.2. Company Overview

12.6.3. Product Offerings

12.6.4. Key Developments

12.6.5. Financial Analysis

12.6.6. SWOT Analysis

12.6.7. Business Strategies

 

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.   

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.  

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

 

Research Methodology

Methodology

Key Inclusions

Methodology

  • A PHP Error was encountered

    Severity: Notice

    Message: Undefined offset: 0

    Filename: pages/reportpage.php

    Line Number: 204

    Backtrace:

    File: /home/absolute/public_html/application/views/pages/reportpage.php
    Line: 204
    Function: _error_handler

    File: /home/absolute/public_html/application/controllers/Report.php
    Line: 153
    Function: view

    File: /home/absolute/public_html/index.php
    Line: 315
    Function: require_once